Weekend Unlimited (CSE:YOLO) will be represented by Canna Candys, with which the Company has signed a letter of intent to acquire as previously announced, at MJ Bizcon in Las Vegas through the conference dates of November 14th – 16th.

Canna Candys brand will establish Weekend Unlimited’s presence in the edibles space as a new cannabis entrant with a fun focused, adult use strategy. As previously noted, Canna Candys has distribution throughout Southern California in over 340 retail locations and is looking to expand in the US throughout states where adult use is legal for recreational or medicinal purposes.


“We are excited to work with Canna Candys to reveal and launch its newly formulated line of hard CBD Candys powered by VESIsorb® at MJ Bizcon,” said Mr. Cody Corrubia, President and CEO of Weekend Unlimited. “The product development leadership and brand savvy of the team at Canna Candys have been a strong addition to Weekend Unlimited’s team and we are working to integrate that expertise with our other brand leadership teams to grow the company’s brand product portfolio,” added Mr. Corrubia.

“Having years of experience pioneering cannabis formulation with candy making craftsmanship, our partnership with VESIsorb® will technologically set us apart from any other edibles company,” said Mr. Paul Chu, CEO of Canna Candys.

“MJ Bizcon will allow us to advance our objectives of rolling out our products across the US. We are seeking distributors and retailers to expand their cannabis offerings with our product lines,” added Mr. Chu.

“As we gear up for multi-brand rollout, we are continuing our partnerships with experienced, licensed producers for packaging and licensing of our premium branded products, leveraging our vertically integrated resources from tissue culture to cultivation, extraction and manufacturing,” noted Mr. Chu.

About VESIsorb®:

VESIsorb® is the leading delivery system innovation for dramatically improving the bioavailability of poorly absorbed ingredients. It is naturally self-assembling colloidal droplet delivery system. Since 2007, close to 200 million consumers in all six major continents have safely and effectively used a VESIsorb® formula. Peer reviewed published study showing 622% faster and better absorption of CBD by the body. www.vesisorb.com

https://www.cannacandyscbd.co/

For further information, please contact:

Mr. Cody Corrubia, President and CEO
Telephone: 1 (236) 317-2812 – Toll free 1(888) 556-YOLO (9656)
E-mail: IR@weekendunlimited.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

Click here to connect with Weekend Unlimited (CSE:YOLO) for an Investor Presentation. 

Source: www.accesswire.com

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less